California Public Employees Retirement System Adaptimmune Therapeutics PLC Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$3.86 - $5.78 $968,088 - $1.45 Million	-250,800 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$4.9 - $6.83 $113,155 - $157,725	-23,093 Reduced 8.43%	250,800 $1.33 Million
Q4 2020 Feb 02, 2021	SELL	$4.0 - $9.2 $21,200 - $48,759	-5,300 Reduced 1.9%	273,893 $1.48 Million
Q3 2020 Nov 05, 2020	BUY	$7.66 - $10.78 $333,102 - $468,779	43,486 Added 18.45%	279,193 $2.23 Million
Q2 2020 Aug 12, 2020	BUY	$2.58 - $12.1 $529,434 - $2.48 Million	205,207 Added 672.81%	235,707 $2.36 Million
Q2 2019 Aug 15, 2019	SELL	$3.23 - $5.41 $16,369 - $27,417	-5,068 Reduced 14.25%	30,500 $123,000
Q4 2018 Feb 08, 2019	SELL	$3.76 - $14.16 $4,136 - $15,576	-1,100 Reduced 3.0%	35,568 $205,000
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $9,328 - $15,295	-1,128 Reduced 2.98%	36,668 $497,000
Q2 2018 Aug 15, 2018	BUY	$10.42 - $13.74 $393,834 - $519,317	37,796 New	37,796 $449,000
Q1 2018 May 11, 2018	SELL	$7.1 - $11.56 $305,264 - $497,022	-42,995 Closed	0 $0
Q4 2017 Feb 06, 2018	BUY	$6.68 - $8.74 $287,206 - $375,776	42,995	42,995 $287,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

Matrix Capital Management Company, LP Waltham, MA

37.7M
Shares

$22.6 Million
1.71% of portfolio
Eco R1 Capital, LLC San Francisco, CA

27.4M
Shares

$16.4 Million
1.13% of portfolio
Nea Management Company, LLC Timonium, MD

17.1M
Shares

$10.2 Million
1.24% of portfolio
Baillie Gifford & CO

16.8M
Shares

$10.1 Million
0.01% of portfolio
Long Focus Capital Management, LLC San Juan, PR

13.3M
Shares

$7.98 Million
0.46% of portfolio

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account